E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal—Tailored Acceleration of AAV Evolution  Dirk Grimm, Sergei Zolotukhin  Molecular.

Slides:



Advertisements
Similar presentations
Tzachi Hagai, Ariel Azia, M. Madan Babu, Raul Andino  Cell Reports 
Advertisements

Volume 9, Issue 2, Pages (February 2004)
414. A Novel Clinical Severity Scoring Measure in Canine X-Linked Myotubular Myopathy: Results Following Systemic AAV Gene Replacement    Molecular Therapy 
M. Fu, G. Huang, Z. Zhang, J. Liu, Z. Zhang, Z. Huang, B. Yu, F. Meng 
Volume 3, Issue 6, Pages (June 2001)
Volume 20, Issue 2, Pages (February 2012)
Methodologic Considerations in the Application of Next-Generation Sequencing of Human TRB Repertoires for Clinical Use  Liwen Xu, Xiaoqing You, PingPing.
Genome-editing Technologies for Gene and Cell Therapy
Volume 14, Issue 1, Pages (July 2013)
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
Total-Genome Analysis of BRCA1/2-Related Invasive Carcinomas of the Breast Identifies Tumor Stroma as Potential Landscaper for Neoplastic Initiation 
Long-Range (17.7 kb) Allele-Specific Polymerase Chain Reaction Method for Direct Haplotyping of R117H and IVS-8 Mutations of the Cystic Fibrosis Transmembrane.
Evolving Gene Therapy in Primary Immunodeficiency
Volume 25, Issue 10, Pages (October 2017)
Reversible Phosphorylation Subserves Robust Circadian Rhythms by Creating a Switch in Inactivating the Positive Element  Zhang Cheng, Feng Liu, Xiao-Peng.
Bone Marrow–Derived Mesenchymal Stromal Cells from Patients with Sickle Cell Disease Display Intact Functionality  Elizabeth O. Stenger, Raghavan Chinnadurai,
KRAS Mutation The Journal of Molecular Diagnostics
Chen Ling, Baozheng Li, Wenqin Ma, George Aslanidi, Arun Srivastava
Functional Dissection of sRNA Translational Regulators by Nonhomologous Random Recombination and In Vivo Selection  Jane M. Liu, Joshua A. Bittker, Maria.
Volume 17, Issue 5, Pages (October 2016)
Volume 20, Issue 2, Pages (February 2012)
Detection of FLT3 Internal Tandem Duplication and D835 Mutations by a Multiplex Polymerase Chain Reaction and Capillary Electrophoresis Assay  Kathleen.
Xiaodong Chen, Gregory C. DeAngelis, Dora E. Angelaki  Neuron 
Selection and Identification of Skeletal-Muscle-Targeted RNA Aptamers
Nicolas Catz, Peter W. Dicke, Peter Thier  Current Biology 
Volume 22, Issue 5, Pages (May 2015)
Larissa V. Furtado, Helmut C. Weigelin, Kojo S. J
Larissa V. Furtado, Helmut C. Weigelin, Kojo S. J
Evolution of the Cancer Stem Cell Model
Volume 25, Issue 3, Pages (March 2017)
Genome-editing Technologies for Gene and Cell Therapy
Volume 22, Issue 11, Pages (November 2014)
Emerging Issues in AAV-Mediated In Vivo Gene Therapy
Molecular Therapy  Volume 20, (May 2012) DOI: /S (16)
Molecular Therapy  Volume 7, Issue 5, (May 2003) DOI: /S (16)
New Technologies Provide Quantum Changes in the Scale, Speed, and Success of SELEX Methods and Aptamer Characterization  Abdullah Ozer, John M Pagano,
Volume 26, Issue 5, Pages (March 2016)
Autosomal-Dominant Woolly Hair Resulting from Disruption of Keratin 74 (KRT74), a Potential Determinant of Human Hair Texture  Yutaka Shimomura, Muhammad.
133. Survival with Normal Neurological Development of the Juvenile Lethal Urea Cycle Defect Arginase Deficient Mouse with AAV Gene Therapy    Molecular.
Volume 21, Issue 8, Pages (August 2013)
Determination of complex subclonal structures of hematological malignancies by multiplexed genotyping of blood progenitor colonies  Francesca L. Nice,
Volume 98, Issue 11, Pages (June 2010)
Sébastien Marti, Jean-Rémi King, Stanislas Dehaene  Neuron 
Tzachi Hagai, Ariel Azia, M. Madan Babu, Raul Andino  Cell Reports 
Statistical Issues in Longitudinal Data Analysis for Treatment Efficacy Studies in the Biomedical Sciences  Chunyan Liu, Timothy P Cripe, Mi-Ok Kim  Molecular.
Volume 19, Issue 4, Pages (April 2011)
Identification of mouse AAV capsid-specific CD8+ T cell epitopes
DNA Looping Facilitates Targeting of a Chromatin Remodeling Enzyme
Volume 11, Issue 9, Pages (June 2015)
Mathieu Nonnenmacher, Harm van Bakel, Roger J Hajjar, Thomas Weber 
Volume 19, Issue 6, Pages (June 2011)
Volume 22, Issue 4, Pages (April 2014)
372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency    Molecular.
521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS  Brad E. Hoffman  Molecular.
Paul B. Mason, Kevin Struhl  Molecular Cell 
Volume 22, Issue 9, Pages (September 2014)
Constitutional Mutations of the hSNF5/INI1 Gene Predispose to a Variety of Cancers  Nicolas Sévenet, Eammon Sheridan, Daniel Amram, Pascale Schneider,
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Schematic design of the SSM
A Second Leaky Splice-Site Mutation in the Spastin Gene
Volume 24, Issue 1, Pages (January 2016)
Qing-Rong Chen, Gordon Vansant, Kahuku Oades, Maria Pickering, Jun S
Fig. 1 General VirScan analysis of the human virome.
Molecular Therapy - Nucleic Acids
Molecular Therapy - Methods & Clinical Development
Thomas Gaj, Benjamin E Epstein, David V Schaffer  Molecular Therapy 
Volume 25, Issue 4, Pages e3 (October 2018)
Volume 22, Issue 11, Pages (November 2014)
Hildegard Büning, Arun Srivastava 
Evolution of Specificity in Protein-Protein Interactions
Presentation transcript:

E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal—Tailored Acceleration of AAV Evolution  Dirk Grimm, Sergei Zolotukhin  Molecular Therapy  Volume 23, Issue 12, Pages 1819-1831 (December 2015) DOI: 10.1038/mt.2015.173 Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Schematic diagram depicting one round of directed molecular evolution which involves three basic steps: diversification, selection, and amplification. Molecular Therapy 2015 23, 1819-1831DOI: (10.1038/mt.2015.173) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Methods for AAV capsid diversification. Depicted are the three strategies that are predominantly found in the literature—DNA family shuffling (DFS), peptide display (PD), and error-prone PCR (epPCR). Also indicated are typical results or recent optimizations, respectively, of each technology. DFS: (1) “good” capsid combining properties of the parental viruses; (2) “bad” capsid in which too many diverse fragments have disrupted functionality; (3) “superior” capsid which has gained novel useful features (pink) not found in any parent. PD: (1) depletion of library from heparin binders (outside the circle), to improve retargeting; (2) use of a chimeric capsid as scaffold for peptide display; (3) same as (2), but using a different AAV wild type. epPCR: (1) rare example of a “winner” capsid which has been improved by a few point mutations; (2) typical wealth of nonfunctional capsids (“losers”) resulting from disruptive mutations; (3) focused PCR randomization in a surface-exposed capsid region. Molecular Therapy 2015 23, 1819-1831DOI: (10.1038/mt.2015.173) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Typical workflow for directed AAV capsid evolution. Depicted from top to bottom are the main steps, from cap gene diversification via different methods (see also Figure 2) and packaging of the resulting mutant pool as a viral library, to selection in cells or animals (positive selection pressure) and, if desired, in the presence of neutralizing anti-AAV antibodies (negative selection pressure). Also indicated is that the ensuing enriched library can be subjected to further rounds of selection after amplification (dashed line) and, again if desired, after additional diversification (dotted line). Eventually, up to five of these iterative cycles will result in one (ideal outcome) or a few mutant capsids that fulfill all requirements and are best tailored for a given application. This figure contains clipart from Servier Medical Art. Molecular Therapy 2015 23, 1819-1831DOI: (10.1038/mt.2015.173) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Schematic depiction of four possible 3D fitness landscapes resulting from plotting of AAV capsid sequence diversity (horizontal axes) against particle fitness (vertical axis). Indicated on the left bottom in each panel is a starting AAV library that is subjected to positive and negative selection pressures, in order to enrich a lead candidate (always circled in red) that managed to climb the highest fitness peak. (a–d) From a to d, the complexity of the landscapes increases which in turn augments chances that other particles may also start to become enriched (such as those in yellow or green), whereas others may be rapidly lost (the one in blue in panel d). An example for panel a is a simple library selection in a single cell type in culture without any additional pressure, whereas the setting in panel d is representative for in vivo biopanning in a live animal. Obviously, such a complex landscape with its many peaks and pits, and hence numerous potential outcomes, puts significant demands on the experimenter to foster the eventual selection of desired capsids. See main text for possible strategies. Molecular Therapy 2015 23, 1819-1831DOI: (10.1038/mt.2015.173) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions